Cargando…
Evolving Role for Pharmacotherapy in NAFLD/NASH
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent, dynamic disease that occurs across the age spectrum and can lead to cirrhosis and hepatocellular carcinoma. There are currently no US Food and Drug Administration (FDA) approved treatments for NAFLD; however, this is a field of active r...
Autores principales: | Attia, Suzanna L., Softic, Samir, Mouzaki, Marialena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877845/ https://www.ncbi.nlm.nih.gov/pubmed/32583961 http://dx.doi.org/10.1111/cts.12839 |
Ejemplares similares
-
Insights into the evolving role of the gut microbiome in nonalcoholic
fatty liver disease: rationale and prospects for therapeutic
intervention
por: Mouzaki, Marialena, et al.
Publicado: (2019) -
The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018) -
Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020) -
More Frequent Clinic Visits Are Associated with Improved Outcomes for Children with NAFLD
por: Lam, Carol, et al.
Publicado: (2016) -
Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022)